C5 and cold agglutinin disease: In the consensus recommendations for AIHAs, published in 2020 (before the approval of sutimlimab), it was agreed by an expert panel that complement inhibition at various levels of the complement cascade (such as with eculizumab, terminal complement [C5] inhibitor) may be a useful treatment approach for CAD in emergencies or for later lines of treatment.24